Bo Xu

MD, PhD
Anatomic Pathology

Cancers Treated:

Specializing In:

Oncologic surgical pathology with emphasis in genito-urologic tumors Thoracic pathology Head/neck pathology

Special Interests:

Histomorphological diagnosis, Classification and staging of urologic and male genital tumors, lung and mediastinal tumors, head & neck tumors Clinicopathologic correlation and translational research on above tumors Translational research and clinicopathological correlation of genitourinary tumors, lung and mediastinal tumors

About Bo Xu

Positions

Roswell Park Comprehensive Cancer Center

  • Associate Professor of Oncology
  • Head of Genitourinary Pathology
  • Director of Autopsy Services
  • Department of Pathology & Laboratory Medicine

Background

Education and Training:

  • PhD - Wright State University Biomedical Science Ph.D. Program, Dayton, OH
  • MD - Nanjing Medical University Faculty of Medicine, Nanjing, China

Residency:

  • Department of Pathology, SUNY at Buffalo, Buffalo, NY
  • Department of Medicine, Section of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Fellowship:

  • Visiting Fellow - Section of Genitourinary Pathology, Indiana University School of Medicine, Indianapolis, IN
  • Fellow - Ontological Surgical Pathology, Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY
  • Post-doctoral Fellow - Howard Hughes Medical Institute Department of Microbiology & Immunology Vanderbilt University School of Medicine, Nashville, TN

Board Certification:

  • Anatomic Pathology, American Board of Pathology
  • Clinical Pathology, American Board of Pathology

Professional Memberships:

  • United States and Canadian Academy of Pathology
  • American Society of Clinical Pathologists
  • College of American Pathologists
  • Association of Molecular Pathology

Publications

Full Publications list on PubMed

1. Xu D, Cao Q, Wang L, Wang J, Xu B, Atwood K, Wei L, Wu Y, Smith GJ, Katsuta E, Takabe K, Chatta G, Guru KA, Goodrich DW and Li QJ. A preclinical study to repurpose Spironolactone for enhancing chemotherapy response in bladder cancer. Molecular Cancer Therapeutics. (Accepted, Nov. 2021)

2. Beshai B, Rehman S and Xu B. Correlation of PD-L1 expression with histological pattern and treatment response in non-small cell lung cancer. Int J Cancer & Clin. Res. 2021. 8 (4):154-158.

3. Menon A, Hussein AA, Attwood KM, White T, James G, Xu B, Petroziello M, Roche C and Kauffman EC. Active surveillance for risk stratification of all small renal masses lacking predefined clinical criteria for intervention. J. Urol., 2021. 206(2):229-239.

4. Yang Y, Attwood K, Bshara W, Mohler JL, Guru K, Xu B, Kalinski P, Chatta K. High intratumoral CD8 + T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate. 2021. 81(1):20-28.

5. Ku S, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbe DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L and Goodrich DW. Rb and p53 cooperate to supperess prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017. 355(6320):78-83